Despite the remarkable therapeutic efficacy and acceptable safety profile of anti-PD–1/PD–L1 antibodies (Abs) in a small subset of patients with platinum-resistant, recurrent, or refractory advanced ovarian cancer, restricted therapeutic responses to ICIs are often observed in patients with ovarian cancer [13,14]. This evidence concerns the gene CD274 and ovarian cancer.